Physician profile
Kai H Yang
NPI 1093851321
$8,223.62
in general payments reported to CMS, 2019-2025
46 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,446 · 2020: $1,524 · 2021: $1,253 · 2022: $1,483 · 2023: $559 · 2024: $328 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.87 |
| Education | $132.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,245.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $883.09 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $725.51 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $665.04 | 2019-2023 | Farxiga |
| Abbvie INC. | $564.58 | 2019-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $422.58 | 2019-2022 | |
| Abbott Laboratories | $370.17 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $364.21 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.58 | 2019-2022 | |
| Amarin Pharma, INC. | $282.78 | 2019-2021 | |
| Corcept Therapeutics | $247.17 | 2019-2023 | Korlym |
| Ipsen Biopharmaceuticals, INC | $208.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.64 | 2021-2022 | |
| Mannkind Corporation | $191.68 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $154.71 | 2019-2023 | Unithroid |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.